(Q26849521)

H. L. DuPont

series ordinal

2

1 reference

language of work or name

1 reference

December 2011

1 reference

Alimentary Pharmacology & Therapeutics

published in

1 reference

volume

34

1 reference

issue

11-12

1 reference

page(s)

1269-81

1 reference

The intestinal microbiota and chronic disorders of the gut.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Circadian rhythm of gastric acid secretion in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Gastric acid secretion and intragastric acidity: measurement in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Duodenal bacterial overgrowth during treatment in outpatients with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Effects of proton pump inhibitors on gastric emptying: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Effect of gastric acid suppressants on human gastric motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Bacterial [correction of baterial] translocation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

The effect of an H2-receptor antagonist on small-bowel colonization and bacterial translocation in newborn rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Hydroxyl radical scavenging reactivity of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Omeprazole attenuates oxygen-derived free radical production from human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Salmonella enterica serovar Typhimurium regulates intercellular junction proteins and facilitates transepithelial neutrophil and bacterial passage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Comparative analysis of extreme acid survival in Salmonella typhimurium, Shigella flexneri, and Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Escherichia coli acid resistance: tales of an amateur acidophile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Pathogenesis of Escherichia coli diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Physical and chemical factors influencing the germination of Clostridium difficile spores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Bile acid concentrations in the refluxate of patients with reflux oesophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Bile acid concentrations in the gastric juice of patients with erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Proton pump inhibitors and risk for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

The human gastric bactericidal barrier: mechanisms of action, relative antibacterial activity, and dietary influences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Inoculum size in shigellosis and implications for expected mode of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Gastric acid secretion and enteric infection in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Cholera, non-vibrio cholera, and stomach acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Low gastric acid as a risk factor for cholera transmission: application of a new non-invasive gastric acid field test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

An outbreak of nosocomial cholera in a 755-bed hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Differences in survival among 13 Listeria monocytogenes strains in a dynamic model of the stomach and small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Overprescribing PPIs: Time for a hospital antacid policy on Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Expert review of the evidence base for prevention of travelers' diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Use of acid-suppressing drugs and the risk of bacterial gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

A case-control study of community-associated Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Clostridium difficile infection in an endemic setting in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Antioxidant properties of omeprazole

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Gastric acid reduction leads to an alteration in lower intestinal microflora

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

The protective role of gastric acidity in neonatal bacterial translocation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case-control study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Diabetes mellitus, anti-secretory drugs and other risk factors for campylobacter gastro-enteritis in adults: a case-control study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Dose-response relationship of lansoprazole to gastric acid antisecretory effects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

The search for effective treatment of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Gastric acid suppression does not promote clostridial diarrhoea in the elderly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

1 reference

7 January 2021

The effect of omeprazole on gastric juice viscosity, pH and bacterial counts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Acid-sensitive enteric pathogens are protected from killing under extremely acidic conditions of pH 2.5 when they are inoculated onto certain solid food sources.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Appropriate acid suppression for the management of gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021

Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04874.X

7 January 2021